Tavo Biotherapeutics Secures $17M to advance glaucoma and retinal disease therapies through clinical development and growth.
Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with ...
Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, announced updates to its Retina Scientific Advisory Board and Executive Leadership Team. These changes are ...
Tavo Biotherapeutics today announced the successful closing of a $17 million Series A financing led by Pureos Bioventures with participation by Polaris Partners and continued support from existing ...
Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal ...
Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes ...
Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with ...
In a recent study published in the journal NPJ Digital Medicine, researchers have developed a deep learning algorithm capable of analyzing high-resolution images of retinal vasculature to detect ...
In March 2026, Boehringer Ingelheim achieved a research milestone under the agreement for SZN-413, reflecting a positive outcome of the IND-enabling GLP toxicology study. The Company received a $5.0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results